https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-04261
Belzutifan versus Active Surveillance for the Treatment of Metastatic Clear Cell Renal Cell Cancer,...
Belzutifan versus Active Surveillance for the Treatment of Metastatic Clear Cell Renal Cell Cancer, BRAVE-ROC Trial
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09840
Belzutifan for the Treatment of Recurrent or Persistent Clear Cell Ovarian or Other Gynecologic...
Belzutifan for the Treatment of Recurrent or Persistent Clear Cell Ovarian or Other Gynecologic Cancer
https://www.merck.com/?s=belzutifan
You searched for belzutifan - Merck.com
searchedbelzutifanmerck
https://www.cancerresearchuk.org/about-cancer/treatment/drugs/belzutifan-Welireg
Belzutifan (Welireg) | Cancer information | Cancer Research UK
Belzutifan (Welireg) is a targeted cancer drug. It is a treatment for some cancers and benign tumours. Find out how you have it and possible side effects.
cancer informationbelzutifanweliregresearchuk
https://www.hmpgloballearningnetwork.com/site/jcp/videos/durable-responses-belzutifan-plus-cabozantinib-advanced-rcc-updated-findings
Durable Responses With Belzutifan Plus Cabozantinib in Advanced RCC: Updated Findings From...
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell...
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT04195750&r=1
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell...
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-belzutifan-vhl-tumors
Belzutifan Approved for Tumors Linked to VHL - NCI
FDA has approved belzutifan (Welireg) to treat adults with von Hippel-Lindau disease (VHL) who have tumors of the kidney, brain, nervous system, or pancreas....
belzutifanapprovedtumorslinkedvhl
https://pmc.ncbi.nlm.nih.gov/articles/PMC11368390/
Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional...
The systemic HIF-2 alpha inhibitor, belzutifan, has been approved for use in patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma,...
von hippel lindaubelzutifanindividualsretinalinstitutional
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-07165
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic...
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL)...
for the
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09840&r=1
Belzutifan for the Treatment of Recurrent or Persistent Clear Cell Ovarian or Other Gynecologic...
Belzutifan for the Treatment of Recurrent or Persistent Clear Cell Ovarian or Other Gynecologic Cancer
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-04261&r=1
Belzutifan versus Active Surveillance for the Treatment of Metastatic Clear Cell Renal Cell Cancer,...
Belzutifan versus Active Surveillance for the Treatment of Metastatic Clear Cell Renal Cell Cancer, BRAVE-ROC Trial
https://www.nice.org.uk/guidance/ta1011/history
History | Belzutifan for treating tumours associated with von Hippel-Lindau disease | Guidance |...
Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults
von hippel lindau diseaseassociated with
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-06635&r=1
Belzutifan or Pembrolizumab Alone versus in Combination for Neoadjuvant Treatment of Clear Cell...
Belzutifan or Pembrolizumab Alone versus in Combination for Neoadjuvant Treatment of Clear Cell Renal Cell Cancer, BLAZE Trial
https://www.cancerresearchuk.org/about-cancer/treatment/drugs/belzutifan-welireg
Belzutifan (Welireg) | Cancer information | Cancer Research UK
Belzutifan (Welireg) is a targeted cancer drug. It is a treatment for some cancers and benign tumours. Find out how you have it and possible side effects.
cancer informationbelzutifanweliregresearchuk
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-belzutifan-mk-6482-for-kidney-cancer-mk-6482-013
A trial of Belzutifan (MK-6482) for kidney cancer (MK-6482-013)
A trial of belzutifan for kidney cancer that has grown into the nearby tissue or spread to another part of the body.
a trialkidney cancerbelzutifanmk6482